Valuation
- Market cap
- 3,659,000
- Revenue TTM
- $30,000
- Net income TTM
- $-162,790,000
- P/E (trailing)
- 0.00
- P/E (forward)
- —
- Profit margin
- -542,633.32%
- Debt to equity
- 0.00
Trading
- Volume
- 1,200
- Avg volume
- 32,192
- Day's range
- $0.02 – $0.02
- Shares out
- 170,997,000
- Stochastic %K
- 10%
- Beta
- 1.45
- Analysts
- —
- Price target
- $1.00
Company profile
Ceryvyn Therapeutics Limited, a clinical-stage biopharmaceutical company, researches and develops therapeutic products based on targeting vascular endothelial growth factors (VEGF) C, D and R3 in Australia and the United States. The company's pipeline includes Sozinibercept, which is in phase 3 to treat wet age-related macular degeneration (Wet AMD), as well as in phase 2 to treat diabetic macular edema (DME). It ser...
Show more
Ceryvyn Therapeutics Limited, a clinical-stage biopharmaceutical company, researches and develops therapeutic products based on targeting vascular endothelial growth factors (VEGF) C, D and R3 in Australia and the United States. The company's pipeline includes Sozinibercept, which is in phase 3 to treat wet age-related macular degeneration (Wet AMD), as well as in phase 2 to treat diabetic macular edema (DME). It serves the biotechnology and healthcare industries. The company was formerly known as Opthea Limited and changed its name to Ceryvyn Therapeutics Limited in July 2026. Ceryvyn Therapeutics Limited was incorporated in 1984 and is headquartered in Melbourne, Australia.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 61 3 9826 0399
- Website
- https://ceryvyn.com
- Address
- Level 9, 505 Little Collins Street, Melbourne, Australia
Latest news
No headlines yet.
